Then, we will discuss the current knowledge about its role in the treatment of ALK-associated cancers, especially in ALK-positive Anaplastic Large Cell Lymphoma (ALCL), ALK-positive Non-Small Cell Lung Carcinoma (NSCLC), Neuroblastoma (NB) and Rhabdomyosarcoma (RMS). This evidence concerns the gene ALK and rhabdomyosarcoma.